Mucositis News and Research

RSS
Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

Medivir appoints Daewoong as South Korean distributor for Xerclear

Medivir appoints Daewoong as South Korean distributor for Xerclear

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

FDA grants orphan drug designation to NephRx's lead product NX001

FDA grants orphan drug designation to NephRx's lead product NX001

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

Access selects BioScrip as exclusive distribution and service partner for MuGard

Access selects BioScrip as exclusive distribution and service partner for MuGard

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access announces agreement to develop oral formulation of proprietary injectable drugs

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Galera Therapeutics completes Series 1 financing

Galera Therapeutics completes Series 1 financing

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010